new hope for serious infections
TRANSCRIPT
New Hope for Serious InfectionsCorporate PresentationSeptember 2019
© Cidara Therapeutics 2019
2
Forward-Looking StatementsThese slides and the accompanying oral presentation contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.
Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding Cidara’s pipeline and whether any of its product candidates may be developed to address unmet medical needs; the effectiveness, safety, long-acting nature of rezafungin; the potential for rezafungin to treat and/or prevent infections; the ability of Cidara to achieve all milestones from its collaboration partner for rezafungin, Mundipharama, and receive related payments; whether the top line results of the STRIVE Part B clinical trial will be supported in the full analysis of the STRIVE Part B clinical data, and whether the success of the STRIVE Part B clinical trial or the post-hoc analysis of the STRIVE Part A and Part B data indicates a successful outcome in the Phase 3 ReSTORE clinical trial, including whether or not rezafungin will meet the primary endpoints in the ReSTORE trial; and, whether Cidara will be able to successfully develop and commercialize rezafungin, as well as the potential market size for rezafungin, ability of rezafungin to capture market share from existing therapies, and the advantages of rezafungin in other settings of care. Certain statements regarding our Cloudbreak platform are also forward-looking including statements regarding whether our Cloudbreak platform can identify product candidates with intrinsic antimicrobial activity and immune engagement that will increase efficacy or represent an improvement over existing anti-infective agents; whether Cloudbreak candidates, including CB-012, will achieve the major attributes believed to be needed in flu such as broad spectrum, superior resistance profile, protection for high-risk populations, expanded efficacy window, long duration of action and rapid onset of activity, or flexible administration; whether results observed with Cloudreak influenza candidates, including CB-012, in-vitro or in animal studies, including, potency and broad coverage, activity against resistant strains, activity in immune compromised patients, extending the treatment window, extended half-life and long duration of action, improved viral clearance in the lungs, improved reduction in inflammatory
cytokines, and a robust safety profile, or other observed attributes, represent an improvement over existing therapies or will also be observed in human use; and whether our Cloudbreak platform can be expanded to identify product candidates to treat or prevent other viral diseases, such as RSV, HIV, Dengue or Zika. This presentation also contains estimates and other statistical data made by independent parties and by Cidara relating to market size and growth and other data about Cidara's industryThese data involve a number of assumptions and limitations, and you are cautioned not to give undue weight to such estimates. Projections, assumptions and estimates of the future performance of the markets in which Cidara operates are necessarily subject to a high degree of uncertainty and risk. Risks that contribute to the uncertain nature of the forward-looking statements include: Cidara’s abilityto obtain additional financing; the success and timing of Cidara’spreclinical studies, clinical trials and other research and development activities; receipt of necessary regulatory approvals for development and commercialization, as well as changes to applicable regulatory laws in the United States and foreign countries; changes in Cidara’s plans to develop and commercialize its product candidates; Cidara’s ability to obtain and maintain intellectual property protection for its product candidates; and the loss of key scientific or management personnel. These and other risks and uncertainties are described more fully in Cidara’s Form 10-K as most recently filed with the United States Securities and Exchange Commission (SEC), under the heading “Risk Factors.” All forward-looking statements contained in this presentation speak only as of the date on which they were made. Cidara undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.
Cidara’s pipeline targets multiple unmet needs
Treatment of Candidemiaand Invasive Candidiasis
Intravenous
Fungal Prophylaxis Intravenous
CLOUDBREAK
ProposedIndication Program Discov. in vitro in vivo
IND-enable Ph 1 Ph 2 Ph 3
Influenza Prevention &Treatment
Antiviral Fc Conjugates (AVCs)
RSV, HIV, Dengue, Zika AVCs
REZAFUNGIN
3
Cloudbreak
Cidara’s pipeline targets multiple unmet medical needs
Rezafungin
4
28%
37%
43%
50%
59%
60%
C. parapsilosis
C. albicans
C. tropicalis
C. glabrata
C. krusei
C. auris
High mortality reflects fungal disease severityOveruse of azoles has driven resistant strains
Crude Mortality (%)n=1,890 cases between 1995 and 20021
>30x mortality risk if:
incorrect drug used treatment delayed ≥24 hrs3
1 Wisplinghoff H et al. Clin Infect Dis. 2004;39(3):309-317 for all species other than C. auris. 2 Clin Infect Dis. 2018 Jan 6; 66(2): 306-311.3 Kollef CID 2012:54 (15 June).
2
5
Invasive fungal disease causes high mortality post transplant
1 The PATH (Prospective Antifungal Therapy) Alliance registry and invasive fungal infections: update 2012 (2012).
90-day mortality % by patient category1
63%
52%
40%
38%
26%
24%
23%
HSCT
Hematologic malignancy
Solid tumor
General medicine
Surgical (nontransplant)
HIV/AIDS
Solid organ transplant
Prophylaxis focusin Phase 3 trial
Bone and marrow transplant
6
Antifungal drug development has dwindled
1980 1990 2000 2010 2020
6 5 1Number of New Antifungals
fluconazole
itraconazole
terbinafineamphotericin lipid forms (3)
micafungin
anidulafungin
voriconazole
caspofungin
posaconazole isavuconazole
7
Rezafungin: An investigational, novel echinocandinantifungal drug
ICAAC 2015
• Designed for prolonged PK
• Designed for high exposures
• Observed absence of toxic degradation products
• Designed for multiple clinical formulations
once weekly dosing in clinical studies
potential for improved efficacy
potential for improved safety
intravenous and subcutaneous under development
Structural modification is designed to yield improved chemical & biological properties
OH
N
NH
OHHNO
O
CH3
OH
HN
NH
HO
N
HO
HO
H3C
O
HO
OH
O
O
O
O
OHN
H3C
O
N+
O-
O
Biafungin (CD101 Acetate)
ON+
8
POLYENES
AZOLES
1ST GEN ECHINOCANDINS
REZAFUNGIN (ECHINOCANDIN)
POLYENES
9
Rezafungin’s role in the treatment of life-threatening Candida infections
AZOLES
1ST GEN ECHINOCANDINS
REZAFUNGIN (ECHINOCANDIN)
Renal toxicitiesOnce-daily IV dosing
High levels of resistanceDrug-drug interactionsHepatic toxicities
Lower front-end exposureOnce-daily IV dosing limits outpatient use
Obtain FDA approval
Spectrum
Oral formulation
No clinically relevant interactions observed in Phase 1 drug-drug interaction trialWell tolerated in clinical trials
High exposure (designed to address critically ill)Once-weekly dosing(possibility for early discharge and outpatients)
Rezafungin overall phase 3 development plan
Phase 3 Treatment Trial
Indication
Phase 3 Size
Duration of Therapy, Endpoints, Comparators
Treatment of candidemia & invasive candidiasis in patients with limited treatment options
184 patients
2 to 4 weeks of treatment,Day 30 all-cause mortality (US)Day 14 global response (EMA)Caspofungin
Phase 3 Prophylaxis Trial
Prophylaxis against Aspergillus, Candida & PCP in patients undergoing allogeneic blood and marrow transplant
462 patients
90 days of prophylaxisDay 90 fungal-free survival (FFS)Fluconazole, posaconazole, Bactrim
1. We plan to commence the ReSPECT trial initially in Europe and Canada.2. Phase 3 Primary Evaluable Population size.
1
10
2
The Rezafungin opportunity spans ID and hematology
Mostly Treatment Mostly Prophylaxis
Cancidas(caspofungin)
~$700M
Noxafil(posaconazole)
~$700M
Infectious Disease Hematology
REZAFUNGIN
Source: Cancidas – IQVIA; Noxafil – 2018 Merck Annual Report11
12
• Ex-U.S. presence in over 120 countries
• Products in diabetes, respiratory, oncology, pain and biosimilars
• Revenues in excess of €2B
• Strong track record of building successful brands
Our partner for rezafungin:
13
Mundipharma has exclusive rights to rezafungin IV ex-US & Japan
Cidara continues to run development programs with Mundipharma support
Cidara receives
• $30M up-front payment
• $9M in equity investment at a 20% premium to recent trading
• $42M in near-term development support• $31.2M in Global Development Cost share• $11.1M near-term milestone creditable against future royalties
• Potential for $568M in total transaction value and tiered double digit royalties in the mid teens1
The terms of our rezafungin partnership
1. Total transaction value includes equity investment, and up-front, cost share and milestone payments.
Comparison of anti-infective deals: 2017-2019
$39M upfront + equity
$42M clinical & CMC support
double-digit royalties in the teens
Product: rezafunginRights: ex-US/JapanStage: P2 data
$19.9M upfront
Undisclosed costcontribution for 2nd
P3 study
$100M regulatory & commercial milestones
Low double-digit royalties
$120M+
$7.5M upfront
$5M on CABP approval
$9M regulatory milestones
$40M commercial milestones
Low double-digit royalties
$61.5M+ $265M+ $725M+
Originator: MelintaLicensee: Menarini
Product: delafloxacinRights: ex-US/JapanStage: Post P3/filing
Originator: ParatekLicensee: Zai Labs
Product: omadacyclineRights: ChinaStage: Post P3
Originator: MelintaLicensee: Menarini
Product: Vabomere, Orbactiv & MinocinRights: ex-US/JapanStage: Approved US
$19.7M upfront
$17.4M VabomereEMA approval
$227M commercial milestones
royalties
Originator: BasileaLicensee: Pfizer
Product: isavuconazoleRights: ex-US/JapanStage: on-market 2+ years
$75M upfront
$650M regulatory and commercial milestones
Double digit royalties
$568M+
ANTIBACTERIAL ANTIFUNGAL
14
STRIVE B Phase 2 data in candidemia & invasive candidiasisCorroborates STRIVE A results and supports ReSTORE Phase 3
15
Week 1 2 3 4 5 6 7 8 9
Day1 5 8 15 22 28
Dose Optional dose
Mycological & clinical response
Overall Response (Mycological & clinical response): 1° ENDPOINT
Mycological & clinical response (IC only)
4535 42 49 56 59
Mycological & clinical response
Week 1 2 3 4 5 6 7 8 9
Day1 5 8 15 22 28 4535 42 49 56 59
Dose
All cause mortality
Analysis Populations: The Intent-to-treat (ITT) population: all randomized subjects The Safety population: all subjects who received any amount of study drug The Microbiological Intent-to-treat population (mITT): all subjects in safety population who had documented
Candida infection
Randomization 2:1
Caspofungin
Rezafungin
Optional dose
P2 STRIVE Part B: Candidemia & Invasive CandidiasisNot powered for inferential statistical analysis
16
Similar to the ReSTORE trial primary endpoint recommended by FDA30-Day All Cause Mortality
15.2%
6.7%
16.3%
Caspofungin
Rezafungin 400/200
Rezafungin 400/400
13.1%
4.4%
15.8%
Caspofungin
Rezafungin 400/200
Rezafungin 400/400
STRIVE B
STRIVE A + B
7/43
1/15
5/33
12/76
2/46
8/61
n/N=
n/N=
Death at Day 30 (%)mITT Population
1
2
3
1
2
3
1. 400 mg dose once weekly for two to four weeks.2. 400 mg dose for the initial week followed by 200 mg dose once weekly for an additional one to three weeks.3. 70 mg day one, followed by daily doses of 50mg. 17
Similar to the ReSTORE trial primary endpoint recommended by EMAInvestigator assessment of clinical response
69.7%
86.7%
65.1%
Caspofungin
Rezafungin 400/200
Rezafungin 400/400
70.5%
80.4%
69.7%
Caspofungin
Rezafungin 400/200
Rezafungin 400/400
STRIVE B
STRIVE A + B
28/43
13/15
23/33
53/76
37/46
43/61
n/N=
n/N=
Clinical Cure (%) at Day 14mITT Population
1. 400 mg dose once weekly for two to four weeks.2. 400 mg dose for the initial week followed by 200 mg dose once weekly for an additional one to three weeks.3. 70 mg day one, followed by daily doses of 50mg.
1
2
3
1
2
3
18
Topline summary of adverse events in Phase 2 safety population
400/400 mg (QWk)
400/200 mg (QWk)
PooledGroups
N=46 N=18 N=64
n (%)
All Related TEAEs 3 (6.5) 0 3 (4.7)
Leading to study D/C 2 (4.3) 0 2 (3.1)
Serious AE 1 (2.2) 0 1 (1.6)
70/50 mg (QD)
N=34
n (%)
5 (14.7)
3 (8.8)
1 (2.9)
REZAFUNGIN CASPOFUNGINAs expected and observed in STRIVE A, the majority of subjects had at least one TEAE and 40-50% had at least one Serious AE, reflecting the high morbidity of the underlying population.
There were no unanticipated or concerning AE trends; % of TEAEs and SAEs were approximately even across study groups.
D/C=discontinuation; TEAE (treatment-emergent adverse event)=AE that occurs after first dose of study drug is administered.
N=81 N=53 N=134
All Related TEAEs 7 (8.6) 6 (11.3) 13 (9.7)
Leading to study D/C 3 (3.7) 0 3 (2.2)
Serious AE 1 (1.2) 1 (1.9) 2 (1.5)
N=68
9 (13.2)
1 (1.5)
2 (2.9)
STRIVE A + B
STRIVE B
Study-Drug-Related TEAEs
19
20
Our Phase 3 trial design mirrors the Phase 2 design
Phase 2
Week 1 2 3 4 5 6 7 8 9
1
Dose Optional dose
Mycological & clinical response: 1° ENDPOINT
All cause mortality
Day 8 15 22 28 45 59
Phase 3
Week 1 2 3 4 5 6 7 8 9
Overall response: 1° ENDPOINT EMA
All cause mortality: 1° ENDPOINT FDA
Objective: demonstrate non-inferiority to caspofungin
Rezafungin (STRIVE A + B, 400/200) vs. Caspofungin (STRIVE A + B)30-Day All Cause Mortality – Post Hoc Analysis*
SUPERIORITY NON-INFERIORITY
0-20% 10%-10%
-24.7% +0.41%
FAVORS REZAFUNGIN FAVORS CASPOFUNGIN
-8.8%
20%
ReSTOREPhase 3 trial endpoint requires upper limit of confidence interval be below 20% threshold
Non-inferiority margin
95% confidence interval
*Using the same analysis method as planned for the Phase 3 study, a two-sided 95% confidence interval (CI) for the observed difference in the ACM rate (Rezafungin 400/200 group minus caspofungin group) was calculated using the unadjusted method of Miettinen and Nurminen.
Post-hoc analyses do not establish effectiveness and should not be assumed to establish the same outcome in Phase 3.
Rezafungin mITT: 2/46= 4.4% ACM; Caspofungin mITT: 8/61= 13.1% ACM
21
Rezafungin (STRIVE A + B, 400/200) vs. Caspofungin (STRIVE A + B)Day 14 Clinical Response – Post Hoc Analysis*
SUPERIORITY NON-INFERIORITY
020% -10%10%
26.6% -6.9%
FAVORS REZAFUNGIN FAVORS CASPOFUNGIN
9.9%
-20%
ReSTOREPhase 3 trial endpoint requires lower limit of confidence interval be above 20% threshold
Non-inferiority margin
95% confidence interval
*Using the same analysis method as planned for the Phase 3 study, a two-sided 95% confidence interval (CI) for the observed difference in the Clinical Response rate (Rezafungin 400/200 group minus caspofungin group) was calculated using the unadjusted method of Miettinen and Nurminen.
Post-hoc analyses do not establish effectiveness and should not be assumed to establish the same outcome in Phase 3.
Rezafungin mITT: 37/46= 80.4% Cure; Caspofungin mITT: 43/61= 70.5% Cure
22
23
Rezafungin in development for prophylaxis in BMT
Host and Macro-environment• Chronic immunosuppression• Novel biologics• Epidemiology - azole resistance
Antifungal therapies• Drug-drug interactions• Toxicities (bone marrow, liver, kidney) • Under-dosing
24
Current fungal prophylaxis requires multiple drugs
Day
Risk of IFIHigh
Low
Post-engraftmentPre-engraftment
CandidaAspergillusPneumocystis
PneumocystisAspergillusCandida
0 10 20 30 6040 70 8050-10
SOC for Candida and
AspergillusPosaconazole or Voriconazole
Day 0 10 20 30 6040 70 8050-10
Anti-PCP: Bactrim, dapsone or atovaquone
Posaconazole or Voriconazole
or…
Fluconazole
Transplant Engraftment
SOC for Pneumocyctis
(PCP)
Fluconazole
25
Rezafungin: potential simplified single drug paradigm
Day 0 10 20 30 6040 70 8050-10SOC for
Candida and Aspergillus
Rezafungin
Risk of IFIHigh
Low
Post-engraftmentPre-engraftment
Day 0 10 20 30 6040 70 8050-10
Transplant Engraftment
SOC for Pneumocyctis
(PCP)
CandidaAspergillusPneumocystis
PneumocystisAspergillusCandida
26
Planned phase 3 prophylaxis trial in BMT patients
Week 1 2 3 4 12
Azole placeboBactrim placebo
Rezafungin5 13
Day 1
17
90 120
Follow upRezafungin Arm (n=~300)
17Week 1 2 3 4 12
Azole*Bactrim
Rezafungin Placebo5 13
Day 1 84 90 120
Comparator Arm (n=~150)
*Fluconazole to start in all patients. Posaconazole optional in patients who develop GVHD per label.
1° Endpoint: Day 90 Fungal-Free Survival
27
Antifungals are historically big drugs globally
BIG PHARMA ANTIFUNGALS Company Product Peak Global Sales ($) Class
MERCK Noxafil(posaconazole) 720M Triazole
Cancidas(caspofungin) 680M 1st Gen
EchinocandinPFIZER Vfend
(voriconazole) 800M Triazole
Diflucan(fluconazole) 1,000M Triazole
Eraxis(anidulafungin) 180M 1st Gen
EchinocandinPFIZER & ASTELLAS Cresemba
(isavuconazole)Launched
in 2015 Triazole
ASTELLAS Mycamine(micafungin) 370M 1st Gen
EchinocandinASTELLAS & GILEAD
Ambisome(amphotericin B) 510M Polyene
Source: IQVIA for all products other than Noxafil (2018 Merck Annual Report) and Diflucan (www.pharmaceuticalonline.com Feb 7, 2000)
Antifungal (Cresemba) launch outpaces recent antibiotics
Cresemba (isavuconazole) is a triazole launched in 2015 by Astellas in the US. In 2017, Pfizer acquired rights to izavuconazole from Basilea for EU, China, 16 Asia Pac countries. Source for sales data: IMS
28
0
10
20
30
1 2 3 4 5 6 7 8 9 10 11 12 13Launch Quarter
U.S. Sales Post Launch: Cresemba vs. Antibiotics
CRESEMBA (ANTIFUNGAL)
AVYCAZ
DALVANCEZERBAXAAVERAGE
ORBACTIV
ANTIBIOTICS
Sale
s ($
M)
Antifungals are valued higher than antibacterials
ANTIBACTERIALDelafloxacin
P3
Approval
1 2 30
Years in market
Omadacycline
Vabomere, Orbactiv & Minocin
0 200 400 600
265
120
Deal ($ million)Rights
Ex-US; Japan
China
Ex-US; Japan
Isavuconazole
Rezafungin
ANTIFUNGAL P3 1 2 30
568
725Ex-US; Japan
Ex-US; Japan
P2P2
P2
Cidara
Opportunity
Commercial
Competition
Business Development
Treatment: in- and outpatientProphylaxis: BMT/Hematology
Outpatient IV pricing & reimbursement (Part B)
13 years since last Candidaor prophylaxis launch
ID & Hem/Onc supportive care companies
“Typical” Abx company
Inpatient treatment
Hospital inpatient DRG
~15 Ph3 programs Multiple launches in 2018-19
ID focused companies
Advantages of expanding outside of the in-hospital market
30
Cidara’s pipeline targets multiple unmet medical needs
31
Rezafungin
Cloudbreak
32
Cloudbreak antiviral conjugates (AVCs) for influenza:Potential single dose universal protection and treatment
10%-60% effective(2004-2018)1
~2-week lag time to achieve full protection2
Difficult to scale, low yields can limit production capacity3
33
Vaccines for influenza have limitations
1. https://www.cdc.gov/flu/professionals/vaccination/effectiveness-studies.htm2. https://www.cdc.gov/flu/protect/keyfacts.htm3. https://www.cdc.gov/flu/professionals/antivirals/summary-clinicians.htm
Viral coverage Patient Manufacturing
Less effective in elderly & immune compromised
Challenging in a pandemic: long, complex production
Strain-specific, variable coverage
34
Treatments for influenza also have limitations
Resistance emerges rapidly
Limited in patients with complicated & severe disease
Resistance Administration Efficacy
48 hour window1
1. https://www.cdc.gov/flu/professionals/antivirals/summary-clinicians.htm
35
Cloudbreak platform – multimodal mechanism of action: intrinsic antimicrobial activity & immune engagement
Binds conserved surface targetDirect antimicrobial activity
Engages innate or adaptive immune system
TARGETING MOIETY
Pathogen ImmuneComponent
Fc MOIETY
36
What would an “ideal” product look like?
Broad spectrum, universal coverage
Superior resistance profile
Protection for High-Risk Populations
Expanded efficacy window
Long duration of action
Rapid onset of activity
Flexible administration
37
Potential for “universal” activity in vivo
Coverage
Resistance
Vulnerable
Efficacy
Duration
Rapid onset
Administration
100%
0%0 14Days
Surv
ival
CB-012 0.4 mg/kg
A/Texas/36/91 H1N1
Neg control (Fc only) 14Days
100%
0%
0
Surv
ival
A/Hong Kong/68 H3N2
CB-012 0.4 mg/kg
14Days
100%
0%0
Surv
ival
B/Malaysia/04
CB-012 0.3 mg/kg
Dose
Single low doses of CB-012 protected mice in lethal infection models
Similar in vivo results found in: A/Puerto Rico/8/34 (H1N1); A/WSN/1933 (H1N1); A/California/07/09 pandemic (H1N1); A/Perth/261/2009 (H275Y).
38
Potential coverage of drug resistant strains
Coverage
Resistance
Vulnerable
Efficacy
Duration
Rapid onset
Administration
14Days
100%
0%
0
Surv
ival
Neg control (Fc only)Tamiflu 20mg/kg10 doses
Dose
CB-012 vs Tamiflu-resistant H1N1
DosesCB-012, 2mg/kg1 dose
1. A/Perth/261/2009, Strain H275Y
Single low dose of CB-012 protected mice in lethal infection model
39
Potential for protection in vulnerable patients
Coverage
Resistance
Vulnerable
Efficacy
Duration
Rapid onset
Administration
Severe Combined ImmunoDeficiencyImmune competentBALB/c SCID miceBALB/c mice
Lethal mouse influenza model (H1N1: A/Puerto Rico/8/34)
0%
Vehicle
0.3 mg/kg
0 14DaysSu
rviv
al
Dose100%
CB-012
0%
Vehicle
0.3 mg/kg
0 14Days
Surv
ival
Dose100%
CB-012
40
Potential expansion of the treatment window
Coverage
Resistance
Vulnerable
Efficacy
Duration
Rapid onset
Administration
0 72 9624HOURS
48
CB-012
Tamiflu
INFECTION
CB-012:Tamiflu:
10 mg/kg20 mg/kg
Dose
Doses
Treatment initiated 72 HOURS post-infection
Fc only
Lethal mouse influenza model (H1N1: TX/36/91)
Single dose of CB-012 given to mice 28 days prior to viral challenge
41
Potential for long-term single dose protection
Coverage
Resistance
Vulnerable
Efficacy
Duration
Rapid onset
Administration
-28 0 14-14
100%
0%
Surv
ival
DAYS
Dose Infect
CB-012
Control
2.5 mg/kg
Lethal influenza model (H1N1: TX/36/91 in mice)
42
Potential rapid therapeutic exposure in key tissues
Coverage
Resistance
Vulnerable
Efficacy
Duration
Rapid onset
Administration
Cmax 1 hr
Con
cent
ratio
n
Lung
Plasma
VACCINES: WEEKS
CB-012 lung distribution10 mg/kg IV dose, mouse
43
Potential for flexible routes of administration
Coverage
Resistance
Vulnerable
Efficacy
Duration
Rapid onset
Administration
CB-012 dosed by different routes5 mg/kg, mouse
SubqIMIV
Cmax 4 hr
Cmax 24 hr
44
Broad safety margin in rats and primatesResults of 14-day toxicity testing
0
20000
40000
60000
Rat Primate
Area under the curve (AUC) for maximum
dose tested (hr*µg/mL)
Therapeutic Margins
AUC required for activity in mice (hr*µg/mL)
15x 10x
Clinical observationsHematologyClinical ChemistryCoagulationUrinalysisHistopathology
NO FINDINGS FOR:
45
Cloudbreak platform: opportunity to expand beyond influenza
INFLUENZA
HIV
RSV
DENGUEZIKA
46
Targeted milestones
2nd half 2019Investor DayPhase 1 subcutaneous
OctoberIDWeekTIMM - STRIVE A&B data
2019 2020MidyearPhase 3 ReSTORE topline
SeptemberPartnership announcement
47
Financial overview
1. Includes $30M up-front and $9.0M equity investment from Mundipharma associated with the partnership announced on September 3, 2019.2. Excludes shares issued to Mundipharma associated with the $9M equity investment made on September 3, 2019.3. Includes 26,767,989 common shares and assumes conversion of 565,231 shares of Series X Convertible Preferred into 5,652,310 common shares at June 30, 2019.
Each share of Series X Convertible Preferred is convertible into 10 shares of common.
Summary Information ($M) June 30, 2019 Mundipharma1
Cash $44.6 $39.0
Common shares issued2 26.8
Common equivalent shares issued3 32.4
48
Cidara is much more than a typical ID company
Rezafungin Treatment
Rezafungin Prophylaxis
Cloudbreak AVC
Strategic Focus
Our Team
Large market with supportive Phase 2 data (STRIVE A + B)
Hem/onc supportive care, high unmet need
Large influenza market. Expansion opportunities
Not a ‘typical’ Infectious Disease company
Experienced creators of shareholder value
New Hope for Serious InfectionsCorporate PresentationSeptember 2019
© Cidara Therapeutics 2019